KEY TAKEAWAYS
- The study aimed to assess the efficacy of bevacizumab in pts with FIGO stage IIIB to IV advanced EOC undergoing PDS.
- The primary endpoints were PFS and OS.
- Bevacizumab conferred significance for common post-PDS use and less promising OS and PFS in advanced cases.
Andre Pfob and the team aimed to evaluate the administration of bevacizumab for patients (pts) with FIGO stage IIIB to IV advanced epithelial ovarian cancer (EOC) undergoing primary debulking surgery (PDS) in pts with the primary disease, employing the real-world data from a German cancer registry.
Researchers identified pts with the initial diagnosis of FIGO stage IIIB to IV EOC reported between 2009 and 2022 from the clinical cancer registry of Baden-Wuerttemberg, Germany. Pts having recurrent disease, comprised, received neoadjuvant chemotherapy, with inoperable disease, or those with insufficient information on systemic treatment or follow-up were excluded from the analysis.
The effect of Bevacizumab + Carboplatin and Paclitaxel (Cb+T+Bev vs. Cb+T) on progression-free survival (PFS) and overall survival (OS) was assessed using Kaplan-Meier statistics and multivariate Cox regression models.
The models were adjusted for age, grading, stage, tumor histology, use of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, and PDS outcome (macroscopic complete gross resection, residual disease ≤1 cm, and >1 cm).
About 835 pts with a median follow-up of 25.1 months were identified from the clinical cancer registry of Baden-Wuerttemberg, Germany. Among them, 542 pts (64.9%) had FIGO stage IIIB/C disease, and 293 (35.1%) had FIGO stage IV disease. Post-operative residual disease status showed complete gross resection in 468 pts (56.0%), ≤1 cm in 181 pts (21.7%), and >1 cm in 186 pts (22.3%).
The median age of the cohort was 63.8 years (SD 11.1). The use of Cb+T+Bev was observed in 40.1% (335/835) of all pts, with rates of 43.8% (205/468) among those with complete gross resection, 38.7% (70/181) among those with ≤1 cm residual disease, and 32.3% (60/186) among those with >1 cm residual disease.
Futher , Cb+T+Bev treatment showed a non-significant association with inclined OS (HR 0.88, 95% CI 0.73-1.07, P=0.216) or PFS (HR 0.95, 95% CI 0.79-1.10, P=0.610) in the entire pts -cohort. In a similar way, the subgroup analysis of pts with residual disease>1 cm, Cb+T+Bev did not demonstrate a statistically significant association with improved OS (HR 0.90, 95% CI 0.61-1.31, P=0.565) or PFS (HR 0.86, 95% CI 0.56-1.32, P=0.483).
The study concluded that Bevacizumab- which is frequently administered to pts with primary FIGO stage IIIB to IV EOC undergoing PDS. However, despite its widespread usage, Bevacizumab did not confer a significant OS or PFS benefit in pts with FIGO stage IIIB to IV EOC.
No funding information was provided.
Source: https://cslide.ctimeetingtech.com/gynae24hybrid/attendee/confcal_1
Pfob A, Surovtsova I, Kokh D, et al. (2024). “Use of bevacizumab for patients with FIGO stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: A German cancer registry study.” Presented at ESMO-GC 2024, (Abstract 69P)
